Form 4: Edwards Lifesciences Executive Wayne Markowitz Reports Stock and Option Grants

Wayne Markowitz, GM & SVP of Surgical at Edwards Lifesciences, reports the acquisition of stock options and restricted stock units under the company's Long-Term Stock Incentive Compensation Program.

Summary

• Wayne Markowitz, a General Manager & SVP at Edwards Lifesciences, filed a Form 4 detailing changes in beneficial ownership.
• On May 7, 2024, Markowitz acquired 3,350 shares of common stock, bringing his total direct holdings to 10,648.5547 shares.
• He also acquired 17,800 employee stock options with an exercise price of $85.84, exercisable starting May 7, 2025, and expiring on May 6, 2031.
• Additionally, Markowitz received 3,350 performance rights, which will vest on May 7, 2027, depending on the achievement of certain performance goals.
• The reported transactions include the quarterly acquisition of shares under the Issuer's Employee Stock Purchase Plan.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it reports routine stock and option grants. It's a standard practice and doesn't indicate any significant positive or negative development.

Positives

• The grant of stock options and restricted stock units aligns Markowitz's interests with those of the shareholders.
• The vesting schedule of the options and restricted stock units encourages long-term performance.

Risks

• The value of the stock options and performance rights is dependent on the future performance of Edwards Lifesciences.
• The actual number of performance rights that vest will depend on the achievement of performance goals, which may not be met.

Future Outlook

The vesting of the restricted stock units and performance rights is contingent upon continued employment and the achievement of certain performance goals over a three-year period.

Industry Context

Executive compensation through stock options and restricted stock units is a common practice in the medical device industry to incentivize performance and align management's interests with shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the medical device industry, similar to companies like Medtronic and Abbott.
• The vesting schedules are also typical, with annual installments over a four-year period being a common practice.
• Performance-based restricted stock units are also used by other companies in the sector to incentivize the achievement of specific financial or strategic goals.

Stakeholder Impact

• The stock and option grants incentivize the executive to improve company performance, which could benefit shareholders.
• The grants do not have a direct impact on employees, customers, suppliers, or creditors.

Key Dates